{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-000801","form_type":"8-K","ticker":"PVLA","cik":"0001583648","company_name":"PALVELLA THERAPEUTICS, INC.","filed_at":"2023-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.706913+00:00","generated_at":"2026-06-20T17:05:26.695193+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Pieris receives $5M milestone from Seagen for Phase 1 start of CD228 x 4-1BB bispecific SGN-BB228","bullets":["Achieved $5M milestone from Seagen upon first patient dosed in Phase 1 study of SGN-BB228 (PRS-346).","Phase 1 trial (NCT05571839) evaluates SGN-BB228 in advanced melanoma and other solid tumors.","This is the first clinical start in Pieris' collaboration with Seagen; two additional programs ongoing.","Pieris has an opt-in option for U.S. co-promotion on one program in the collaboration."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-000801","json":"https://secwatch.observer/filing/0001437749-23-000801.json","markdown":"https://secwatch.observer/filing/0001437749-23-000801.md","text":"https://secwatch.observer/filing/0001437749-23-000801.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1583648/000143774923000801/0001437749-23-000801-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1583648/000143774923000801/pirs20230110c_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T17:05:26.695193+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}